<DOC>
	<DOCNO>NCT02576717</DOCNO>
	<brief_summary>The purpose trial determine safety efficacy RPC1063 patient relapse multiple sclerosis .</brief_summary>
	<brief_title>A Multi-Site , Open-Label Extension Trial Oral RPC1063 Relapsing Multiple Sclerosis</brief_title>
	<detailed_description>The trial open label extension study . Eligible patient RPC01-201 , RPC01-301 , RPC01-1001 trial diagnose relapse Multiple Sclerosis ( RMS ) enrol receive study drug end trial Sponsor discontinue development program .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Eligibility Criteria : Completed one parent trial : RPC01201 , RPC01301 RPC011001 Does condition would require withdrawal one parent trial ( RPC01201 , RPC01301 , RPC011001 ) Has condition require treatment prohibit medication Ability provide write informed consent compliant schedule protocol assessment Patients reproduction potential ( male female ) must practice acceptable method birth control</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>MS</keyword>
	<keyword>RMS</keyword>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Relapsing Multiple Sclerosis</keyword>
</DOC>